Drug Trial Radar · NCT01715805
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
Last checked: Nov 19, 2026Latest source record: Aug 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,022
Actual
Start
Nov 15, 2012
Primary completion
Jun 24, 2016
Study completion Jun 24, 2016
Sponsor
- Lead sponsor
- Forest LaboratoriesAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- Gedeon Richter Ltd.
- First posted
- Oct 29, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD
Conditions
- Major Depressive Disorder
Interventions
CariprazineDrug
Cariprazine capsules 1.5 to 4.5 mg/day
PlaceboDrug
Dose-matched placebo capsule once per day
Antidepressant Therapy (ADT)Drug
ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Montgomery-Asberg Depression Rating Scale (MADRS) at Baseline in the Double-Blind PeriodTime frame: Baseline (Week 8)
- Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) in the Double-Blind PeriodTime frame: Baseline (Week 8) to Week 16
Locations
85 sites in 2 countries. Site status is shown where the registry gives one.
Forest Investigative Site 032
Tucson, Arizona
Forest Investigative Site 018
Little Rock, Arkansas
Forest Investigative Site 029
Little Rock, Arkansas
Forest Investigative Site 084
Cerritos, California
Forest Investigative Site 085
Culver City, California
Forest Investigative Site 082
Garden Grove, California
Forest Investigative Site 022
Newport Beach, California
Forest Investigative Site 004
Oceanside, California
Forest Investigative Site 090
Rancho Mirage, California
Forest Investigative Site 078
Redlands, California
Forest Investigative Site 080
Redlands, California
Forest Investigative Site 007
San Diego, California
Forest Investigative Site 054
San Diego, California
Forest Investigative Site 031
Temecula, California
Forest Investigative Site 048
Denver, Colorado
Forest Investigative Site 037
Coral Springs, Florida
Forest Investigative Site 053
Fort Myers, Florida
Forest Investigative Site 023
Hallandale, Florida
Forest Investigative Site 071
Hialeah, Florida
Forest Investigative Site 006
Leesburg, Florida
Forest Investigative Site 026
Miami, Florida
Forest Investigative Site 075
Miami, Florida
Forest Investigative Site 027
North Miami, Florida
Forest Investigative Site 074
North Miami, Florida
Forest Investigative Site 036
Oakland Park, Florida
Forest Investigative Site 051
Orlando, Florida
Forest Investigative Site 044
South Miami, Florida
Forest Investigative Site 008
Tampa, Florida
Forest Investigative Site 019
Winter Park, Florida
Forest Investigative Site 060
Atlanta, Georgia
Forest Investigative Site 024
Atlanta, Georgia
Forest Investigative Site 017
Marietta, Georgia
Forest Investigative Site 047
Smyrna, Georgia
Forest Investigative Site 070
Chicago, Illinois
Forest Investigative Site 013
Hoffman Estates, Illinois
Forest Investigative Site 063
Libertyville, Illinois
Forest Investigative Site 062
Maywood, Illinois
Forest Investigative Site 072
Naperville, Illinois
Forest Investigative Site 010
Oak Brook, Illinois
Forest Investigative Site 068
Skokie, Illinois
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.